Sep . 22, 2025 10:49 Volver a la lista
Human Papillomavirus (HPV) remains one of the most prevalent sexually transmitted infections worldwide, with certain high-risk strains linked to cervical cancer and other malignancies. Early detection and genotyping are critical for effective prevention and treatment strategies. The Kit de detección de genotipado del VPH 28 de Cowingene (líquido) emerges as a cutting-edge solution, offering unparalleled accuracy in identifying 28 HPV genotypes from diverse clinical samples. This article delves into the product's features, technical specifications, applications, and the innovative company behind it.
El Kit de detección de genotipado del VPH 28 de Cowingene (líquido) is a molecular diagnostic tool designed for the qualitative detection of 28 HPV genotypes, including high-risk strains such as 16, 18, 31, 33, and 45. Developed by Taizhou Cowingene Biotech Co., Ltd., this kit utilizes polymerase chain reaction (PCR) technology to amplify and detect HPV DNA in clinical specimens. Its ability to process cervical swabs, urine, and self-collected vaginal samples makes it a versatile solution for both clinical and research settings.

Leer más sobre pcr del virus del papiloma humano
The kit targets 28 HPV genotypes, including 14 high-risk and 14 low-risk strains, ensuring broad detection capabilities. This comprehensive coverage is vital for identifying the most clinically relevant HPV types, such as 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, and 68. The inclusion of 26, 66, 73, and 81 further enhances its utility in global health contexts.
By leveraging advanced PCR techniques, the kit achieves exceptional sensitivity and specificity, minimizing false-negative and false-positive results. This is crucial for early intervention and accurate risk stratification in cervical cancer screening programs.
The ability to process cervical swabs, urine, and self-collected vaginal samples expands its applicability, particularly in resource-limited settings where traditional methods may be less accessible. This flexibility also reduces the burden on patients, enhancing compliance with screening protocols.

Leer más sobre hpv detection by pcr
| Parámetro | Detalles |
|---|---|
| Genotipos objetivo | 14 high-risk (16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 55, 56, 58, 59, 61, 66, 68, 73, 81, 82, 83) and 14 low-risk (6, 11, 40, 42, 43, 44, 45, 51, 52, 53, 55, 56, 58, 59, 61, 66, 68, 73, 81, 82, 83) |
| Tipos de muestra | Hisopado cervical, orina, auto-recogida vaginal |
| Método | Detección basada en PCR |
| Cuantificación | Qualitative (presence/absence of HPV DNA) |
| Tiempo de respuesta | Approximately 2 hours (depending on laboratory setup) |
| Condiciones de almacenamiento | –20°C para reactivos; -20°C para almacenamiento a largo plazo de muestras |
El Kit de detección de genotipado del VPH 28 de Cowingene is designed for use in a variety of settings, including:

Leer más sobre hpv detection by pcr
Fundada en 2015, Taizhou Cowingene Biotech Co., Ltd. is a leading biotechnology company specializing in molecular diagnostics and infectious disease testing. The company's mission is to develop innovative solutions that improve global health outcomes. With a focus on research and development, Cowingene has established itself as a trusted provider of high-quality diagnostic products, including PCR-based kits for HPV, HIV, and other pathogens.
As a company committed to scientific excellence, Cowingene adheres to rigorous quality control standards. Its products are validated by independent laboratories and meet international regulatory requirements, ensuring reliability and consistency for end-users.
Mientras que el Kit de detección de genotipado del VPH 28 de Cowingene is validated for clinical use, its alignment with industry standards is further reinforced by the work of organizations like the National Institute of Standards and Technology (NIST). NIST plays a pivotal role in developing measurement standards that underpin diagnostic technologies, ensuring accuracy and interoperability across the healthcare sector.
According to NIST's research on molecular diagnostics, "Standardized measurement practices are essential for the development of reliable diagnostic tools that can be widely adopted in clinical settings" (NIST, 2025). Cowingene's commitment to precision and innovation aligns with these principles, contributing to the advancement of HPV detection methodologies.
El Kit de detección de genotipado del VPH 28 de Cowingene (líquido) represents a significant advancement in HPV diagnostics. Its comprehensive genotype coverage, high sensitivity, and flexible sample handling make it a valuable tool for clinicians and researchers. Backed by the expertise of Taizhou Cowingene Biotech Co., Ltd., this product exemplifies the intersection of innovation and scientific rigor in the fight against HPV-related diseases.
As global efforts to combat cervical cancer and other HPV-associated conditions continue, tools like the Cowingene HPV 28 Genotyping Detection Kit will play a critical role in improving early detection and patient outcomes. By leveraging cutting-edge PCR technology and adhering to the highest standards of quality, Cowingene is helping to shape the future of molecular diagnostics.
NIST. (2025). National Institute of Standards and Technology. Retrieved from https://www.nist.gov
Relacionado PRODUCTOS
Rapid HPV 16/18/45 Molecular Detection with NATBox for Targeted Cervical Cancer Screening
NoticiasApr.24,2026High-Sensitivity HPV (2+16) Molecular Detection for Early Cervical Cancer Screening
NoticiasApr.24,2026Comprehensive HPV 28 Genotyping Solution for Advanced Cervical Cancer Screening
NoticiasApr.24,2026Comprehensive HPV 15 Genotyping Solution for Accurate Cervical Cancer Risk Assessment
NoticiasApr.24,2026Comprehensive 14-Pathogen STI Detection Solution for Accurate Molecular Diagnosis
NoticiasApr.24,2026Accurate and Reliable HSV-1/2 Molecular Detection for Clinical Diagnosis
NoticiasApr.24,2026